Cadrenal Therapeutics, Inc. Operating Cash Flow
Cadrenal Therapeutics, Inc. (CVKD) reported Operating Cash Flow of -$5.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Cadrenal Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.23M.
- Cadrenal Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.00M.
- Cadrenal Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.57M.
- Cadrenal Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.36M.
- Cadrenal Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$12.60M.
- Cadrenal Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$7.36M.
- Cadrenal Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$3.53M.
| Period end | Net Cash Provided by (Used in) Operating Activities 2 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 5 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 8 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 11 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$5.24M 10-Q · filed 2026-08-13 | -$7.81M derived: sum of 3 quarters · filed 2026-08-13 | -$10.16M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$3.00M 10-Q · filed 2026-05-07 | -$5.57M derived: sum of 2 quarters · filed 2026-05-07 | -$7.93M derived: sum of 3 quarters · filed 2026-05-07 | -$10.96M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.93M derived: sum of 2 quarters · filed 2026-03-31 | -$7.95M derived: sum of 3 quarters · filed 2026-08-13 | -$12.60M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | -$2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$5.38M derived: sum of 2 quarters · filed 2026-08-13 | -$10.03M 10-Q · filed 2025-11-10 | -$11.82M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$3.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$7.67M 10-Q · filed 2026-08-13 | -$9.47M derived: sum of 3 quarters · filed 2026-08-13 | -$11.67M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$4.65M 10-Q · filed 2026-05-07 | -$6.44M derived: sum of 2 quarters · filed 2026-05-07 | -$8.64M derived: sum of 3 quarters · filed 2026-05-07 | -$10.17M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$3.99M derived: sum of 2 quarters · filed 2026-03-31 | -$5.52M derived: sum of 3 quarters · filed 2026-03-31 | -$7.36M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | -$2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$3.73M derived: sum of 2 quarters · filed 2025-11-10 | -$5.57M 10-Q · filed 2025-11-10 | -$6.26M derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | -$1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$3.37M 10-Q · filed 2025-08-11 | -$4.06M derived: sum of 3 quarters · filed 2025-08-11 | -$4.69M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | -$1.84M 10-Q · filed 2025-05-08 | -$2.53M derived: sum of 2 quarters · filed 2025-05-08 | -$3.16M derived: sum of 3 quarters · filed 2025-05-08 | -$3.95M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$694.45K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$1.32M derived: sum of 2 quarters · filed 2025-03-13 | -$2.12M derived: sum of 3 quarters · filed 2025-03-13 | -$3.53M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$627.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.42M derived: sum of 2 quarters · filed 2024-11-07 | -$2.84M 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | -$795.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$2.21M 10-Q · filed 2024-08-07 | ||||||
| 2023-03-31 | -$1.41M 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | -$1.20M 10-K · filed 2024-03-11 | |||||||
| 2022-09-30 | -$914.55K 10-Q · filed 2023-11-09 | |||||||
| 2022-06-30 | -$496.84K 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | -$43.70K 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |